articleJournal of Clinical OncologyDec 5, 2005BRONZE OA

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

RJRobert J. MotzerMDM. Dror MichaelsonBGBruce G. RedmanGRGary R. HudesGWGeorge Wilding

Fox Chase Cancer Center · Memorial Sloan Kettering Cancer Center · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE: Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC. PATIENTS AND METHODS: Patients with metastatic RCC and progression on first-line cytokine therapy were enrolled onto a multicenter phase II trial. SU11248 monotherapy was administered in repeated 6-week cycles of daily oral therapy for 4 weeks, followed by 2 weeks off. Overall…

Citation impact

1,631
total citations
FWCI
132.24
Percentile
100%
References
45
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Medicine
  • Sunitinib
  • Sunitinib malate
  • Renal cell carcinoma
  • Vascular endothelial growth factor
  • Platelet-derived growth factor receptor
  • Tyrosine-kinase inhibitor
  • Growth factor receptor
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.